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Bcl11b is a transcription factor important for T cell development and also a tumor-suppressor gene that is
hemizygously inactivated in ~10 % human T cell acute lymphoblastic leukemia (T-ALL) and several murine T-ALL
models, including ATM−/− thymic lymphomas. Here we report that heterozygous loss of Bcl11b (Bcl11b+/−)
unexpectedly reduced lethal thymic lymphoma in ATM−/− mice by suppressing lymphoma progression, but not
initiation. The suppression was associated with a T cell-mediated immune response in ATM−/−Bcl11b+/− mice,
revealing a haploid insufficient function of Bcl11b in immune modulation against lymphoma and offering an
explanation for the complex relationship between Bcl11b status with T-ALL prognosis.Correspondence/findings
Bcl11b is a transcription factor that is “monoallelically”
inactivated in ~10 % of human T cell acute lymphoblastic
leukemia (T-ALL) [1–3] and several murine T-ALL models,
including ATM−/− thymic lymphomas [4–6]. Both human
and murine T-ALLs retain at least one intact copy of
Bcl11b, indicating that Bcl11b is a bona fide haploinsuffi-
cient tumor-suppressor gene. Complete loss of the Bcl11b
gene abrogates T cell development and gain of NK cell
phenotype, revealing a critical role of Bcl11b in T cell
lineage commitment [7–10]. Conditional inactivation of
both copies of Bcl11b in double-positive (DP) T cells leads
to overproduction of innate CD8+ single-positive (SP) T
cells [11] and compromises T-regulatory cell function [12].
Yet, hemizygous loss of Bcl11b has no measurable impact
on T cell function [7–10] and the mechanism by which it
promotes T-ALL remains elusive.
To address this, we characterized Bcl11b+/−ATM−/− mice
[6, 13]. ATM kinase is a master regulator of the DNA dam-
age responses [14]. ATM−/− mice routinely succumb to
immature T cell lymphomas sharing molecular features
with human T-ALL. Of the ATM−/− thymic lymphomas,* Correspondence: sz2296@columbia.edu
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rocal t(12;14) translocation [6, 15]. Conditional inactivation
of Bcl11b in T cells via LckCre eliminates recurrent t(12;14)
translocations from ATM−/− thymic lymphomas, suggesting
Bcl11b as the target of the large chromosome 12 deletion
[16]. ATM−/−Bcl11b+/− mice were born at expected fre-
quency (Additional file 1: Figure S1A). Thymocyte develop-
ment and peripheral T and B cell repertoire in young
(4 week) ATM−/−Bcl11b+/− mice were indistinguishable
from that of ATM−/− mice, displaying reduced surface
TCRβ/CD3ε expression in DP cells and a partial blockade
at the DP to SP transition characteristic for ATM-
deficiency [6, 17] (Additional file 1: Figure S1B).
While we initially expected Bcl11b-deficiency to ac-
celerate ATM-deficient thymic lymphomas based on
its frequent inactivation in T-ALLs, hemizygous-
deletion of Bcl11b prevented lethal thymic lymphoma
in ~50 % ATM−/− mice and only 2/11 ATM−/−Bcl11b+/−
mice developed overt thymic lymphomas (Fig. 1a). The
median survival of ATM−/−Bcl11b+/− mice was signifi-
cantly longer than that of ATM−/− controls (167 vs.
106 days, p < 0.01) (Fig. 1a). Analyses of 3- and 10-month-
old ATM−/−Bcl11b+/− mice revealed clonal expansion of
immature (surfaceTCRβlow) thymocytes in 3-month, but
not 10-month-old ATM−/−Bcl11b+/− mice (Fig. 1b, c). T
cell lymphomas from 3-month-old ATM−/−Bcl11b+/− mice
retained both WTand null alleles of Bcl11b, consistent with
the lack-of-LOH in T-ALL (Fig. 1d). Despite the clonalarticle distributed under the terms of the Creative Commons Attribution License
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Fig. 1 Heterozygous loss of Bcl11b suppresses the progression, but not the initiation of ATM-deficient thymic lymphomas. a Thymic lymphoma-
free survival of ATM−/− and ATM−/−Bcl11b+/− mice. Median survival of ATM−/− and ATM−/−Bcl11b+/− cohorts was 106 and 169 days, respectively.
p value for log-ranking test is 0.0061. b Representative flow cytometry analyses of the thymus from control and ATM−/−Bcl11b+/− mice at 3 or
10 months of age. c Southern blot analyses of EcoRI digested genomic DNA from kidney (K), thymus (T), enlarged submandibular lymph nodes
(L), or spleen (S) from ATM−/−Bcl11b+/− mice probed with TCRβ probes (Jβ1.6 or 2.7), TCRδ constant region (Cδ) or chromosome 14 amplification
region (Amp) [6]. d Southern blot analyses of Bcl11b locus on KpnI digested genomic DNA with Bcl11b probe [13]
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Fig. 2 Heterozygous loss of Bcl11b induces an inflammatory/immune response in ATM−/− mice. a Representative pictures of enlarged
submandibular lymph nodes, dermatitis, and splenomegaly in ATM−/−Bcl11b+/− mice. b Histopathologic analysis of the submandibular lymph
nodes and spleen in ATM−/−Bcl11b+/− mice. c Flow cytometry analysis shows significant enrichment of CD8+ SP T cells in the peripheral blood,
but not the spleen of 10-month-old ATM−/−Bcl11b+/− mice
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thymic lymphomas failed to progress to lethal disease
(Additional file 1: Figure S1C), suggesting that heterozygous
Bcl11b-deficiency suppresses the progression, but not the
initiation of ATM−/− thymic lymphomas.
Notably, almost all ATM−/−Bcl11b+/− mice developed
variable degrees of splenomegaly, excessive submandibular
lymph node (LN) enlargement that manifested to fatal
airway obstruction (non-lymphoma-related death), and
dermal inflammation commencing at 2–3 months of age
(Fig. 2a). In contrast to normal lymphocyte profiles in 3-
month-old ATM+/+(+/−)Bcl11b+/− mice (Additional file 1:
Figure S2A and S2B), histologic analyses consistently
revealed a lymphocyte-mediated inflammatory/immune
disorder in ATM−/−Bcl11b+/− mice characterized by
marked plasmacytosis with reactive germinal centers
(B220+IgM+ Bcl6+CD138− B cells) in submandibular LN,
reactive follicular hyperplasia of the white pulp and in-
creased extramedullary hematopoiesis in the red pulp in
the spleen (Fig. 2b and Additional file 1: Figure S2C), and
acute and chronic dermal inflammation in the skin. While
a cell-autonomous function of Bcl11b deletion on epider-
mal integrity cannot be ruled out [13], the splenic and LN
changes noted raised the possibility of an autoimmune
disorder, which could have contributed to the lack of
tumor progression in ATM−/−Bcl11b+/− mice. Corres-
pondingly, 10-month tumor-free ATM−/−Bcl11b+/− mice
accumulated activated CD8+ T cell in PB (Fig. 2c).
Our data suggest that in an ATM-deficient back-
ground, heterozygous Bcl11b deficiency tilts immune
homeostasis and limits the expansion, but not the initi-
ation of ATM-deficient thymic lymphomas. Notably,
homozygous Bcl11b deletion suppressed melanoma in
murine models [18]. Given the role of Bcl11b in T cell
lineage commitment, CD8+ T cell development, and T-
reg function, our data suggest that heterozygous Bcl11b
deficiency can modulate anti-tumor immune response
despite the lack of measurable T cell development de-
fects in Bcl11b+/− mice [7–10]. This role of Bcl11b in
immune modulation and tumor suppression might ex-
plain the discrepancies between Bcl11b status (mutation,
deletion, and downregulation) and T-ALL prognosis in
different studies [1–3, 19]. It also suggests that Bcl11b is
likely lost later during T-ALL development, as early de-
letion likely causes autoimmune dysfunction, analogous
to TNFAIP3 (A20) in DLBCL [20].Additional file
Additional file 1: Figure S1. Characterization of T cell development in
ATM−/−Bcl11b+/− mice. (A) Actual and expected offspring from breeding
between Bcl11b+/−ATM+/− and ATM+/− mice. The p value calculated based
on chi-squared test is 0.89. (B) Representative flow cytometric analysis
of pre-malignant thymocytes from WT, ATM−/− and ATM−/−Bcl11b+/−mice (4–6 weeks). Figure S2. Analyses of autoimmunity in ATM−/−Bcl11b+/−
mice. (A) Flow cytometric analysis of the spleen, bone marrow, and lymph
nodes from 3-month and 10-month-old ATM−/−Bcl11b+/− mice. Notably, the
frequency of the CD11b+ myeloid cells increases in the spleen of ATM−/−
Bcl11b+/− mice, consistent with increased extramedullary hematopoiesis in
the red pulp seen in Fig. 2b. (B) Flow cytometric analyses of the thymus and
spleen (SPL) from 3-month-old littermate ATM+/+Bcl11b+/+ (WT), Bcl11b+/−,
ATM+/−Bcl11b+/− mice. Double negative (DN) staining was performed on
gated CD8-CD4-CD19-TCRγ/δ− thymocytes. Homozygous deletion of Bcl11b
dramatically increased the number of phenotypical NK cells [8, 9]. The
percentage of NK1.1+ or CD8+ cells does not significantly increase in the
thymus and spleen of 3-month-old Bcl11b+/− mice. (C) Immunohistochemical
staining with germinal center marker Bcl6 and plasma cell marker CD138 of
the enlarged submandibular lymph nodes. (PDF 2082 kb)
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